Compare PRPL & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPL | NNVC |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1M | 35.2M |
| IPO Year | 2015 | 2008 |
| Metric | PRPL | NNVC |
|---|---|---|
| Price | $5.80 | $1.32 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $0.65 | N/A |
| AVG Volume (30 Days) | 27.8K | ★ 280.1K |
| Earning Date | 04-28-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 152.75 | 10.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $468,725,000.00 | N/A |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $6.68 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.28 | $0.85 |
| 52 Week High | $10.00 | $2.23 |
| Indicator | PRPL | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 45.44 | 40.68 |
| Support Level | $0.51 | $1.26 |
| Resistance Level | $10.00 | $1.47 |
| Average True Range (ATR) | 0.64 | 0.08 |
| MACD | -0.58 | -0.01 |
| Stochastic Oscillator | 0.44 | 17.31 |
Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.